2.95p+0.00 (+0.00%)31 May 2024, 16:29
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Valirx PLC Fundamentals

Company NameValirx PLCLast Updated2024-05-31
IndustryBiotechnologySectorHealthcare
Shares in Issue132.349 mMarket Cap£3.90 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.02EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0071Debt Equity Ratio0.0037
Asset Equity Ratio1.0780Cash Equity Ratio0.0602
Quick Ratio1.2752Current Ratio2.64
Price To Book Value1.2130ROCE0

Valirx PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Valirx PLC Company Financials

Assets202320222021
Tangible Assets£242,625.00£5,561.00£13,278.00
Intangible Assets£2.32 m£2.51 m£2.71 m
Investments000
Total Fixed Assets£2.56 m£2.51 m£2.72 m
Stocks£69,002.0000
Debtors£99,050.00£76,228.00£66,122.00
Cash & Equivalents£174,684.00£1.14 m£593,672.00
Other Assets000
Total Assets£3.13 m£3.98 m£3.52 m
Liabilities202320222021
Creditors within 1 year£214,654.00£127,575.00£68,220.00
Creditors after 1 year£11,857.00£22,070.00£41,335.00
Other Liabilities000
Total Liabilities£226,511.00£149,645.00£109,555.00
Net assets£2.90 m£3.83 m£3.41 m
Equity202320222021
Called up share capital£102,320.00£90,174.00£65,049.00
Share Premium£27.87 m£26.77 m£24.49 m
Profit / Loss-£2.30 m-£2.60 m-£1.68 m
Other Equity£3.22 m£4.05 m£3.60 m
Preference & Minorities-£314,623.00-£224,539.00-£184,867.00
Total Capital Employed£2.90 m£3.83 m£3.41 m
Ratios202320222021
Debt Ratio£0.00£0.01£0.01
Debt-to-Equity£0.00£0.01£0.01
Assets / Equity1.07801.07801.0780
Cash / Equity0.06020.06020.0602
EPS-£0.02-£0.03-£0.02
Cash Flow202320222021
Cash from operating activities-£1.77 m-£1.71 m-£1.26 m
Cashflow before financing-£656,612.00£543,805.00-£1.25 m
Increase in Cash-£962,793.00£543,805.00-£1.25 m
Income202320222021
Turnover£9,600.0000
Cost of sales£1,440.0000
Gross Profit£8,160.0000
Operating Profit-£2.30 m-£2.59 m-£1.68 m
Pre-Tax profit-£2.30 m-£2.60 m-£1.68 m

Valirx PLC Company Background

SectorHealthcare
ActivitiesValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers,specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.
Latest Interim Date24 Aug 2023
Latest Fiscal Year End Date15 May 2024

Valirx PLC Directors

AppointedNamePosition
2013-10-08Mr. James Nicholas ThornileyNon-Executive Director,Chairman
2020-04-14Dr. George MorrisExecutive Director,Chief Operating Officer
2020-04-14Dr. Satu VainikkaExecutive Director,Chief Executive Officer
2024-05-15Mr. Gerald DeslerExecutive Director,Chief Financial Officer and Company Secretary
2022-06-30Mr. Kevin J AlexanderNon-Executive Director,Company Secretary
2010-04-01Dr. Jacob MicallefExecutive Director,Chief Technical Officer
2024-04-15Ms. Stella PanuNon-Executive Director
2007-10-25Mr. Anthony Roger MooreNon-Executive Director,Chairman
2020-07-03Mr. Oliver de Giorgio-MillerNon-Executive Director,Chairman
2019-05-31Mr. Seppo Olavi MakinenNon-Executive Director
2024-05-15Mr. Martin LampshireNon-Executive Director
2024-05-15Dr. Suzanne Dilly Executive Director,Chief Executive Officer
2024-05-15Dr. Kevin Paul Cox Non-Executive Director,Chairman
2024-04-22Mr. Adrian Michael Patrick de CourceyNon-Executive Director

Valirx PLC Contact Details

Company NameValiRx PLC
Address16 Upper Woburn Place, London, WC1H 0BS
Telephone+44 2030084416
Websitehttps://www.valirx.com

Valirx PLC Advisors

StockbrokerBeaufort Securities Ltd
Phone+44 2073828300
Fax+44 2073828400
SolicitorPinsent Masons LLP
Phone+44 2074187000
Fax+44 2074187050
AuditorAdler Shine LLP
Phone+44 2083713000
Fax+44 2083713099
BankRoyal Bank of Scotland PLC
Financial PR AdviserPeckwater PR
RegistrarCapita Asset Services
Phone+44 8704027573
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880